Summary:
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED 8 WEEK
STUDY TO EVALUATE THE SAFETY AND EFFICACY OF NEBIVOLOL AND VALSARTAN
GIVEN AS A FIXED-DOSE COMBINATION IN PATIENTS WITH STAGE 1 OR STAGE 2
ESSENTIAL HYPERTENSION
Qualified Participants Must:
• Have Diagnosed and Documented Hypertension
Qualified Participants May Receive:
$50 per visit (after the pre-screen visit)
Free Study Medication
Free Study Related Healthcare